GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NovaBay Pharmaceuticals Inc (AMEX:NBY) » Definitions » Operating Income

NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Operating Income : $-5.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is NovaBay Pharmaceuticals Operating Income?

NovaBay Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-0.80 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.00 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. NovaBay Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-0.80 Mil. NovaBay Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $3.73 Mil. Therefore, NovaBay Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 was -21.41%.

Good Sign:

NovaBay Pharmaceuticals Inc operating margin is expanding. Margin expansion is usually a good sign.

NovaBay Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 15.10% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NovaBay Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 was -52.92%. NovaBay Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -101.17%.


NovaBay Pharmaceuticals Operating Income Historical Data

The historical data trend for NovaBay Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovaBay Pharmaceuticals Operating Income Chart

NovaBay Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.40 -6.43 -8.86 -7.68 -5.00

NovaBay Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.69 -1.73 -1.36 -1.12 -0.80

NovaBay Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovaBay Pharmaceuticals  (AMEX:NBY) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NovaBay Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-3.192 * ( 1 - 0% )/( (7.606 + 4.458)/ 2 )
=-3.192/6.032
=-52.92 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

NovaBay Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.192/( ( (1.623 + max(1.926, 0)) + (1.383 + max(1.378, 0)) )/ 2 )
=-3.192/( ( 3.549 + 2.761 )/ 2 )
=-3.192/3.155
=-101.17 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.916 + 3.493 + 0.333) - (1.774 + 1.042 + 0)
=1.926

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.759 + 2.877 + 0.388) - (1.7 + 0.946 + 0)
=1.378

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

NovaBay Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-0.798/3.727
=-21.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


NovaBay Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2000 Powell Street, Suite 1150, Emeryville, CA, USA, 94608
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Executives
Tommy Law officer: Interim CFO 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Jeffrey Kunin officer: President, DERMAdoctor, LLC 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Audrey Kunin officer: Chief Product Officer 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Justin Hall officer: General Counsel 5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608
Yongxiang Zheng director NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316
Julie Garlikov director 2420 17TH STREET, SUITE 220, DENVER CO 80202
Andrew D. Jones officer: CFO and Treasurer 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Mijia Wu director SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA
Jian Ping Fu 10 percent owner LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125
Wang Xu officer: NEO - Sr Mgr and Controller 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Swan Sit director 95 JACKSON STREET, NEWTON MA 02459
Yenyou Zheng director 1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9
Xiaopei Wang director 2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109
Jason Philip Raleigh officer: Interim CFO and Treasurer 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Pioneer Pharma (hong Kong) Co Ltd 10 percent owner FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000